IN VITRO AND IN VIVO EFFICACY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN EPITHELIAL OVARIAN CANCER WITH HER2/NEU OVEREXPRESSION

被引：0
|
作者：
Mutlu, Levent [1 ]
Manavella, Diego [1 ]
Bellone, Stefania [1 ]
Santin, Alessandro [1 ]
机构：
[1] Yale Univ, Obstet Gynecol & Reprod Sci, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷
关键词：
D O I：
10.1136/ijgc-2022-igcs.106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP015/#546
引用
收藏
页码：A54 / A54
页数：1
相关论文
共 50 条
  • [31] Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer
    Rose, Peter G.
    Kelley, Johanna A.
    Feldman, Myra
    Krivanek, Kevin
    JCO PRECISION ONCOLOGY, 2023, 7
  • [32] Real world data on Trastuzumab Deruxtecan (T-DXd) induced Interstitial Lung disease (ILD) in HER2 positive metastatic breast cancer patients at the Kent Oncology Centre
    Mohammed, S.
    Moss, C.
    Harper-Wynne, C.
    CLINICAL ONCOLOGY, 2025, 38
  • [33] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Cobbina, Enoch
    Cheng, Shen
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Altwerger, Gary
    Black, Jonathan D.
    Dugan, Katherine
    Pettinella, Francesca
    Masserdotti, Alice
    Riccio, Francesco
    Bianchi, Anna
    Zammataro, Luca
    de Haydu, Christopher
    Buza, Natalia
    Hui, Pei
    Wong, Serena
    Huang, Gloria S.
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 145 - 152
  • [35] Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd)
    Alder, Laura
    Trapani, Dario
    Van Swearingen, Amanda
    Khasraw, Mustafa
    Anders, Carey
    Lin, Nancy
    Sammons, Sarah
    CANCER RESEARCH, 2022, 82 (12)
  • [36] HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Drago, Joshua Z.
    Pareja, Fresia
    Jhaveri, Komal L.
    Walsh, Elaine M.
    Ku, Geoffrey Yuyat
    Maron, Steven Brad
    Janjigian, Yelena Y.
    Robson, Mark E.
    Reis-Filho, Jorge S.
    Modi, Shanu
    Razavi, Pedram
    Chandarlapaty, Sarat
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Shitara, K.
    Enzinger, P. C.
    Mohapatra, A. S.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S200 - S200
  • [38] Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer
    Tsao, Li-Chung
    Wang, John S.
    Ragusa, Joey
    Liu, Bushangqing
    McBane, Jason
    Spasojevic, Ivan
    Fan, Ping
    Trotter, Timothy N.
    Lyerly, Herbert Kim
    Hartman, Zachary C.
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [39] Population Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2positive breast cancer subjects: analyses across 12 Phase 1-3 studies
    Li, Claire
    Henning, Stefanie
    Patel, Kashyap
    Hui, Katrina
    van der Vleuten, Gerly
    Abutarif, Malaz
    Garimella, Tushar
    Khatri, Amit
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)
    Hingorani, Pooja
    Zhang, Wendong
    Kurmasheva, Raushan
    Zhang, Zhongting
    Wang, Yifei
    Xu, Zhaohui
    Roth, Michael
    Gill, Jonathan
    Harrison, Douglas
    Erickson, Stephen
    Kolb, Edward A.
    Smith, Malcolm
    Houghton, Peter
    Gorlick, Richard
    CANCER RESEARCH, 2020, 80 (16)
12345